MG
CYCN icon

Michael Gelband’s Cyclerion Therapeutics CYCN Stock Holding History

Michael Gelband’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,135
Closed -$70K – 2233
2021
Q3 		$70K Buy
1,135
+57
+5% +$3.73K ﹤0.01% 1940
2021
Q2 		$84K Buy
+1,078
New +$67.5K ﹤0.01% 2175
2020
Q4 		– Sell
-867
Closed -$105K – 2034
2020
Q3 		$105K Buy
+867
New +$99.1K ﹤0.01% 1584

Other funds holding CYCN

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Michael Gelband's CYCN Position: Q4 2021 in Review

Michael Gelband sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 1,135 shares — an estimated $70K sold.

Michael Gelband first reported a position in CYCN in Q3 2020 and held it in 3 quarters. The position peaked at $105K in Q3 2020. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

  • Michael Gelband reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Michael Gelband sold 1,135 Cyclerion Therapeutics shares in Q4 2021, an estimated $70K.
  • Michael Gelband first reported a position in Cyclerion Therapeutics in Q3 2020 and held it in 3 quarters.
  • Michael Gelband's Cyclerion Therapeutics position peaked at $105K in Q3 2020.
  • 56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.